ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,475,000 | +54.6% | 1,500,000 | +100.0% | 0.83% | +77.8% |
| Q2 2023 | $34,597,500 | +15.0% | 750,000 | 0.0% | 0.47% | +5.2% |
| Q1 2023 | $30,075,000 | -13.4% | 750,000 | 0.0% | 0.45% | -14.1% |
| Q4 2022 | $34,747,500 | +11.9% | 750,000 | 0.0% | 0.52% | -9.6% |
| Q3 2022 | $31,058,000 | -30.6% | 750,000 | 0.0% | 0.57% | -35.1% |
| Q2 2022 | $44,745,000 | +167.9% | 750,000 | +226.1% | 0.88% | +189.8% |
| Q1 2022 | $16,703,000 | – | 230,000 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |